Detalles de la búsqueda
1.
A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor.
Cancer Control
; 31: 10732748241244586, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38581169
2.
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles.
Invest New Drugs
; 41(3): 483-492, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37162707
3.
Decision and timing of safety-related labeling changes for new drugs in Japan: Comparison with the United States and the European Union.
Pharmacoepidemiol Drug Saf
; 32(12): 1331-1340, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37395168
4.
Oncology drug lag in Japan: has it improved over the last decade?
Int J Clin Oncol
; 28(11): 1451-1460, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37561368
5.
Impact of the Economic Status of the Patient's Country of Residence on the Outcome of Oncology Clinical Trials.
Oncologist
; 27(3): e244-e250, 2022 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274721
6.
Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial.
BMC Cancer
; 22(1): 277, 2022 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35291959
7.
Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis.
Cancer Control
; 29: 10732748221140694, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36748438
8.
Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers' Information Sources.
Int J Technol Assess Health Care
; 38(1): e25, 2022 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35297362
9.
A comparison of decision and timing of safety related labeling changes for new drugs approved both in Japan and the United States.
Pharmacoepidemiol Drug Saf
; 30(5): 561-572, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33559352
10.
Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall population.
Int J Clin Oncol
; 26(2): 296-304, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33057897
11.
Increased availability of drugs is correlated with the number of patients diagnosed thereafter: Data analysis of 45 intractable diseases.
J Clin Pharm Ther
; 46(5): 1319-1325, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33959993
12.
Medicine characteristics affecting the time to guidance publication by National Institute for Health and Care Excellence in the single technology appraisal process.
Int J Technol Assess Health Care
; 38(1): e11, 2021 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34933699
13.
Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer.
Int J Clin Oncol
; 25(5): 851-860, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31950377
14.
Post-marketing safety-related regulatory actions on first-in-class drugs: A double-cohort study.
J Clin Pharm Ther
; 45(3): 496-502, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31846100
15.
Population/regional differences in efficacy of 3 drug categories (antidiabetic, respiratory and psychotropic agents) among East Asians: A retrospective study based on multiregional clinical trials.
Br J Clin Pharmacol
; 85(6): 1270-1282, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30735569
16.
Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Eur J Clin Pharmacol
; 75(9): 1193-1200, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31129731
17.
Current state of therapeutic development for rare cancers in Japan, and proposals for improvement.
Cancer Sci
; 109(5): 1731-1737, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29878624
18.
Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
Ann Pharmacother
; 52(7): 632-638, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29424239
19.
Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
Pharmacoepidemiol Drug Saf
; 27(12): 1393-1401, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30094880
20.
Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
Pharmacoepidemiol Drug Saf
; 27(12): 1402-1408, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30324671